meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs pemetrexed plus platin
vs non active control
vs placebo
All patients
PD-L1 < 1%
PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
progression or deaths (PFS)
AE (grade 3-4)
AE leading to death (grade 5)
SAE (any grade)
deaths (OS)
malignant mesothelioma (mMS) - 1st line (L1)
malignant mesothelioma (mMS) - 1st line (L1)
malignant mesothelioma (mMS) - 2nd line (L2)
malignant mesothelioma (mMS) - 2nd line (L2)
versus placebo
nivolumab alone vs. placebo
1
certainty unassessable
-26%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open